Pfizer said on Tuesday its cancer drug Padcev, in combination with Merck's Keytruda, significantly improved survival rates in ...

The combination of Padcev, a bladder cancer drug from Pfizer Inc. and Astellas Pharma Inc., and Merck & Co.’s blockbuster ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

The rising bladder cancer star that is the combination of Pfizer and Astellas’ Padcev and Merck’s Keytruda is looking to set ...

Pfizer said its antibody-drug conjugate Padcev extended survival when combined with the immunotherapy Keytruda in some ...

Merck in 2019 inked a deal to evaluate the combination of its blockbuster cancer drug Keytruda with Pacdev from Astellas and Seagen, which Pfizer acquired in a $43 billion deal that closed in late ...

New trial results reveal enfortumab vedotin and pembrolizumab significantly improve survival for muscle-invasive bladder ...

Bladder cancer survivors have spoken out on the 'red flag' warning sign and 'most common' symptom they all experienced before ...

When bladder cancer affects only the inner lining of the bladder, it is called squamous cell carcinoma. Bladder cancer is also categorized by how invasive it is, notes the NCI.

“I’m loving life right now,” said Sanders, who's drawn headlines for his health in the past, but with the focus largely on ...

Sanders said during a news conference on Monday that the cancer was found when he went for a precautionary annual CT scan; he ...

In some cases, the cancer spreads to other parts of the body. The most common symptom for bladder cancer is blood in the urine, which can cause urine to look orange, pink, or rarely, dark red.